APA (7th ed.) Citation

C, M., L, P., MLM, S., JR, C., LK, S., V, H., . . . M, M. (2026). A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis. European journal of neurology, 33(2), e70507. https://doi.org/10.1111/ene.70507

Chicago Style (17th ed.) Citation

C, Maersk-Moller, et al. "A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis." European Journal of Neurology 33, no. 2 (2026): e70507. https://doi.org/10.1111/ene.70507.

MLA (9th ed.) Citation

C, Maersk-Moller, et al. "A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis." European Journal of Neurology, vol. 33, no. 2, 2026, p. e70507, https://doi.org/10.1111/ene.70507.